NCT02522572 - Quantitating the Impact of Plerixafor | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

September 30, 2020

Study Completion Date

October 31, 2020

Conditions

Transplants and Implants

Interventions

DRUG

plerixafor

Plerixafor will be dosed subcutaneously and administered based on group assignment.

DRUG

Bortezomib

Bortezomib will be given via IV push over 3-5 seconds and administered based on group assignment.

OTHER

plasmapheresis

Plasmapheresis will be administered based on group assignment.

Trial Locations (2)

RECRUITING

The Christ Hospital, Cincinnati

RECRUITING

University of Cincinnati, Cincinnati